SPG-302 has been developed to target the synapse in nerve cells. The synapse is the site of contact between two nerve cells or the nerve cell and muscle and enables communication via chemical signals. This communication is key for brain control of muscles for movement. One major aspect of MND is the loss of these synapses. SPG-302 has been designed to increase the number of synapses in nerve cells.
The first part of this trial took place in 2023, where the drug was tested on healthy volunteers. The second part of the trial will commence shortly and will test the drug in MND patients, but only for a very short period (4 weeks). This trial will be testing to see whether the drug behaves in the same way in patients as it does in healthy volunteers and will also measure any changes in patients that may occur. At the completion of the four week trial participants will move to an open-label extension (OLE) component, which will allow them to keep receiving the drug for up to a year.
Recruitment for this trial has commenced in both Adelaide and Brisbane. Recruitment has not yet commenced at the Sydney trial site, however it is anticipated that this will commence shortly.
| SA | Flinders Medical Centre | Dr David Schultz 08 8204 4187 david.schultz@sa.gov.au |
| QLD | Royal Brisbane and Women's Hospital | Susan Heggie 07 3646 1478 Susan.Heggie@health.qld.gov.au Kathryn Thorpe 07 3346 5011 kathryn.thorpe@health.qld.gov.au |
| NSW | Macquarie University | Recruitment has not yet commenced at this site. |
For more information visit clinicaltrials.gov
